JP2013510832A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510832A5
JP2013510832A5 JP2012538360A JP2012538360A JP2013510832A5 JP 2013510832 A5 JP2013510832 A5 JP 2013510832A5 JP 2012538360 A JP2012538360 A JP 2012538360A JP 2012538360 A JP2012538360 A JP 2012538360A JP 2013510832 A5 JP2013510832 A5 JP 2013510832A5
Authority
JP
Japan
Prior art keywords
par
antagonist
influenza
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012538360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510832A (ja
Filing date
Publication date
Priority claimed from EP09306098A external-priority patent/EP2335717A1/en
Application filed filed Critical
Publication of JP2013510832A publication Critical patent/JP2013510832A/ja
Publication of JP2013510832A5 publication Critical patent/JP2013510832A5/ja
Pending legal-status Critical Current

Links

JP2012538360A 2009-11-16 2010-11-15 A型インフルエンザウイルス感染症の治療または予防用のpar−1アンタゴニスト Pending JP2013510832A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306098A EP2335717A1 (en) 2009-11-16 2009-11-16 PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections
EP09306098.6 2009-11-16
PCT/EP2010/067516 WO2011058183A1 (en) 2009-11-16 2010-11-15 Par-1 antagonists for use in the treatment or prevention of influenza virus type a infections

Publications (2)

Publication Number Publication Date
JP2013510832A JP2013510832A (ja) 2013-03-28
JP2013510832A5 true JP2013510832A5 (https=) 2013-12-26

Family

ID=41728318

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012538360A Pending JP2013510832A (ja) 2009-11-16 2010-11-15 A型インフルエンザウイルス感染症の治療または予防用のpar−1アンタゴニスト

Country Status (8)

Country Link
US (2) US8802623B2 (https=)
EP (2) EP2335717A1 (https=)
JP (1) JP2013510832A (https=)
KR (1) KR20120098696A (https=)
CN (1) CN102711787A (https=)
AU (1) AU2010317917B2 (https=)
CA (1) CA2780835A1 (https=)
WO (1) WO2011058183A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2834621A1 (en) * 2011-05-12 2012-11-15 Universite Laval Par1 inhibitors for use in the treatment or prevention of paramyxoviridae infections
WO2013070256A2 (en) * 2011-11-07 2013-05-16 The Scripps Research Institute Protease activated receptor-1 (par1) derived cytoprotective polypeptides and related methods
JP2016520570A (ja) * 2013-04-22 2016-07-14 アンスティテュ ナシオナル ドゥ ラ ルシェルシュ アグロノミックInstitut National De La Recherche Agronomique A型インフルエンザウイルス感染の治療又は予防に使用するためのpar−4アンタゴニスト
HK1223096A1 (zh) 2013-09-25 2017-07-21 Vertex Pharmaceuticals Incorporated 用作par-2信號通路抑制劑的咪唑並噠嗪
WO2015124570A1 (en) * 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
EP3240561A4 (en) * 2014-12-29 2018-07-11 Academia Sinica Method for treating influenza a virus infection
CN116999558B (zh) * 2023-10-07 2024-01-02 中国人民解放军军事科学院军事医学研究院 Par1作为用于治疗或者抑制埃博拉病毒的靶点的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5688768A (en) 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
WO1993018141A1 (en) * 1992-03-02 1993-09-16 Biogen, Inc. Thrombin receptor antagonists
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6017890A (en) 1998-02-19 2000-01-25 Ortho-Mcneil Pharmaceutical, Inc. Azole peptidomimetics as thrombin receptor antagonists
US6630451B1 (en) * 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
GB0213286D0 (en) 2002-06-10 2002-07-24 Univ Edinburgh Par-2-Activating peptide derivative and pharmaceutical composition using the same
AU2005294265A1 (en) * 2004-10-06 2006-04-20 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
CA2592142A1 (en) * 2004-12-22 2006-06-29 Emory University Therapeutic adjuncts to enhance the organ protective effects of postconditioning
US20080318960A1 (en) 2005-05-26 2008-12-25 Ethan Burstein PAR2-modulating compounds and their use
US20070123508A1 (en) 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
ES2400322T3 (es) * 2008-02-05 2013-04-09 Sanofi Derivados de SF5 como inhibidores de PAR-1, su preparación y utilización como medicamento
EP2427205A2 (en) 2009-05-04 2012-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Par2 agonists for use in the treatment or prevention of influenza virus type a infections

Similar Documents

Publication Publication Date Title
JP2013510832A5 (https=)
ECSP24034690A (es) Formulación tópica para un inhibidor de jak
JP2013542247A5 (https=)
ME02400B (me) Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
JP2011528713A5 (https=)
JP2012255026A5 (https=)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2010222367A5 (https=)
ME02547B (me) Inhibitori hepatitis c virusa
JP2012532874A5 (https=)
CL2014000492A1 (es) Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
CL2007003742A1 (es) Compuestos derivados heterociclicos, inhibidores de protein quinasas activadas por mitogenos; proceso de preparacion; composicion farmaceutica; articulo de manufactura; y uso para el tratamiento de enfermedades tales como trastornos hiperproliferativ
JP2014521735A5 (https=)
PE20142353A1 (es) Ansolvatos de sal de noribogaina
JP2013534248A5 (https=)
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
WO2009033732A3 (en) Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
EP2753348A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE
BR112014006356A2 (pt) nova composição farmacêutica resistente ao abuso para o tratamento de dependência de opioide
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
JP2012505883A5 (https=)
JP2016539156A5 (https=)
JP2016516074A5 (https=)
JP2016507547A5 (https=)
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية